Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 3960

NextCure inks ADC deal with Simcere Zaiming

$
0
0
NextCure will be paying up to $745 million for the ex-Greater China rights to an early-stage antibody-drug conjugate developed by a Shanghai-based drug developer. Simcere Zaiming's asset, called SIM0505, targets CDH6. It’s currently in a ...

Viewing all articles
Browse latest Browse all 3960

Trending Articles